XML 43 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1
Related Parties Balances and Transactions (Details Textual) - USD ($)
 2 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 26, 2017
Jan. 26, 2017
Sep. 30, 2015
Jun. 30, 2017
Dec. 31, 2016
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Sep. 30, 2016
Related Parties Balances and Transactions (Textual)                  
Amount received from BioFirst Corporation     $ 22,517 $ 953,000     $ 953,000   $ 6,500,000
Due to shareholder, YuanGene Corporation     46,586           0
Interest expense     28,500   $ 3,753 47,500 $ 3,753 10,170
Accrued interest             9,500   0
Payment to LionGene Corporation for consulting service         $ 70,000        
Co-development agreement [Member]                  
Related Parties Balances and Transactions (Textual)                  
Description of payment settlement schedule The Company entered into a co-development agreement (the "Co-Dev Agreement") with Rgene Corporation, a shareholder of the Company, to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum with Biolite. Per the payment term, $90,000 which is 3% of the total agreement of $3,000,000 to be paid by Rgene, was received upon signing of the agreement by both parties.                
BioFirst Corporation [Member]                  
Related Parties Balances and Transactions (Textual)                  
Amount received from BioFirst Corporation       $ 950,000     $ 950,000  
BioFirst Corporation [Member] | Loan Agreement [Member]                  
Related Parties Balances and Transactions (Textual)                  
Amount received from BioFirst Corporation   $ 950,000              
Loan bears interest terms   Loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to remit the interest payment monthly to the lender.              
Loan maturity date   Feb. 01, 2018